Montis Biosciences

Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers. Leveraging its patient-centric discovery platform, Montis is advancing unique and potent antibodies to bring new treatment options to those patients. Montis lead program, MB01, focuses on modulating the multifaceted roles of C1q, the activator of the classical complement pathway and a key immune system mediator in neuroinflammatory and autoimmune disorders. Unlike existing C1q-targeting approaches that focus on blocking the classical complement pathway, Montis has discovered novel anti-C1q antibodies, capable of targeting C1qs complement-independent functions with or without inhibiting the classical...

Neuroinflammation,oncology,neurodegeneration,and autoimmune disorders

Montis biosciences operates in the Biotechnology research industry.

Montis biosciences's revenue is 11m - 100m

Montis biosciences has 11 - 50 employees.